The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Value-Based Payment to Overtake Fee-For-Service by 2020
July 1st 2014A new survey by McKesson Health Solutions and released at America's Health Insurance Plan's Institute 2014 conference examined the state of value-based reimbursement, and found that of the existing value-based models, payers and hospitals/health systems predict pay-for-performance (P4P) will experience the most growth
Patricia M. LoRusso, DO, Joins Yale Cancer Center to Further Innovation in Cancer Research
July 1st 2014Patricia M. LoRusso, DO, widely-regarded as a leading expert on developing new cancer drugs through clinical trials, will join Yale Cancer Center in August as a Professor of Medicine and Associate Director of Innovative Medicine at Yale Cancer Center.
ODAC Votes Against Maintenance Olaparib in BRCA-Positive Ovarian Cancer
June 25th 2014The FDA's Oncologic Drugs Advisory Committee voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations.
340B Drug Program Under Scrutiny
June 25th 2014Hospitals, community health centers, and clinics that participate in the federal 340B drug pricing program are finding themselves under scrutiny from some members of Congress and the pharmaceutical industry because of recent expansion of the Affordable Care Act.
A Third of Practice Managers Surveyed Expect Value-based Contracts to Hurt Bottom Line
June 19th 2014A third of practice managers and health care executives who participated in a survey about value-based contracts said they expected the agreements to hurt the bottom line of their institution or practice
As Clinicians Attempt to Show Meaningful Use, Smartphone and Tablet Use Declines
June 18th 2014Health care professionals, including primary care physicians, cardiologists, oncologists, and psychiatrists are using their mobile devices (ie, smartphones and tablets) less, as compared to last year, and find themselves spending more time on a daily basis in front of their desktop computers
Ramucirumab Misses Primary Endpoint in Phase III HCC Trial
June 11th 2014The phase III REACH trial, which examined ramucirumab (Cyramza) for the second-line treatment of patients with hepatocellular carcinoma (HCC), failed to meet its primary endpoint of overall survival (OS), as announced by Eli Lilly and Company, the sponsor of the study and developer of the drug.
Vogelzang Sees Early Chemo Strategy as Landmark Change in Prostate Cancer Therapy
June 10th 2014Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.
Bundled Payment Strategies Move Beyond the Pilot Stage
June 10th 2014Bundled payments are no longer being relegated to pilot program status, according to a report from the Health Care Incentives Improvement Institute (HCI3). Instead, more and more public and private payers are committing to this model as a core payment and delivery reform strategy.
Ovarian Cancer Subtypes May Predict Response to Bevacizumab
June 9th 2014Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
WellPoint Study Shows Office-based Practices Deliver Less Costly Cancer Care
June 5th 2014A retrospective analysis of pharmacy and medical claims conducted by WellPoint shows that the costs to treat and care for cancer patients can be 3% to 14% less, depending on cancer type, when it is provided by oncologist-owned practices versus hospital-owned practices.
CMS-Sponsored Website Provides ICD-10 Guidance
May 29th 2014Although the deadline for ICD-10 implementation has been moved to October 1, 2015, the Centers for Medicare & Medicaid Services (CMS) has developed, in collaboration with physicians, a free tool that is specialty-specific and offers customizable, actionable advice and tips to ease physician practices through the transition to ICD-10.